Latest Imatinib Stories
Scientists from the Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation have found a specific mutation that leads to the development of severe autoimmune kidney disease in mice.
Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors For GIST patients who were assigned to Gleevec, more than nine out of 10 remained cancer-free based on a 14-month median follow up EAST HANOVER, N.J., Dec.
- Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH - Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can damage key organs - New long-term data from major independent breast cancer trial at SABCS to report on optimal post-surgery treatment strategy, Femara vs.
CytRx, a biopharmaceutical company, has announced that INNO-406, the company's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with chronic myeloid leukemia.
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).
GPC Biotech has reported preclinical data on RGB-286638, the company's multi-targeted protein kinase inhibitor, that supported the potential utility of RGB-286638 against some hematological malignancies.
Oregon Health & Science University today announced that Philip H. and Penny Knight have pledged to give $100 million to the OHSU Cancer Institute.
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578).
EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).